» Articles » PMID: 35532261

Icariin Inhibits Gastric Cancer Cell Growth by Regulating the Hsa_circ_0003159/miR-223-3p/NLRP3 Signaling Axis

Overview
Journal Hum Exp Toxicol
Publisher Sage Publications
Specialty Toxicology
Date 2022 May 9
PMID 35532261
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to clarify the expression and role of hsa_circ_0003159 in gastric carcinogenesis, and validate the protective effects of Icariin (ICA) against gastric cancer (GC) cell growth through the in vitro and in vivo experiments. The levels of hsa_circ_0003159, microRNA (miR)-223-3p and NLRP3 were measured by Quantitative real time Polymerase Chain Reaction or western blot. The cell counting kit (CCK)-8 was used to determine cell proliferation. The target relationship of miR-223-3p/hsa_circ_0003159 and miR-223-3p/NLRP3 was predicted by bioinformatics and validated by the dual-luciferase reporter and pull-down assays. Xenograft model was constructed to assess the roles of hsa_circ_0003159 and protective effects of ICA in GC in vivo. Results showed that hsa_circ_0003159 was downregulated in GC cell lines and its overexpression promoted GC cell viability. MiR-223-3p was identified as a target of hsa_circ_0003159. By competitively sponging miR-223-3p, hsa_circ_0003159 positively regulated NLRP3 expression. MiR-223-3p mimics reversed the suppressive effect of hsa_circ_0003159 on GC cell viability and cell pyroptosis. Importantly, ICA inhibited GC cell viability and triggered GC cell pyroptosis by regulating the hsa_circ_0003159/miR-223-3p/NLRP3 axis in vitro and in vivo. In conclusion, this study indicated ICA inhibits GC cell growth by regulating the hsa_circ_0003159/miR-223-3p/NLRP3 signaling axis. This study not only reveals the mechanism of gastric carcinogenesis but also provides potential molecular targets and therapeutic tools for its treatment.

Citing Articles

Targeting programmed cell death via active ingredients from natural plants: a promising approach to cancer therapy.

Li Q, Tong Y, Chen J, Xie T Front Pharmacol. 2024; 15:1491802.

PMID: 39584140 PMC: 11582395. DOI: 10.3389/fphar.2024.1491802.


Novel role of circRNAs in the drug resistance of gastric cancer: regulatory mechanisms and future for cancer therapy.

Lu L, Gao Z, Jin L, Geng H, Liang Z Front Pharmacol. 2024; 15:1435264.

PMID: 39314750 PMC: 11416928. DOI: 10.3389/fphar.2024.1435264.


Flavonoids and Gastric Cancer Therapy: From Signaling Pathway to Therapeutic Significance.

Cai J, Tan X, Hu Q, Pan H, Zhao M, Guo C Drug Des Devel Ther. 2024; 18:3233-3253.

PMID: 39081701 PMC: 11287762. DOI: 10.2147/DDDT.S466470.


Application of pyroptosis score in the treatment and prognosis evaluation of gastric cancer.

Li L, Liao A Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 48(12):1882-1889.

PMID: 38448382 PMC: 10930744. DOI: 10.11817/j.issn.1672-7347.2023.230258.


Emerging roles of circular RNAs in tumorigenesis, progression, and treatment of gastric cancer.

Ma Q, Yang F, Xiao B, Guo X J Transl Med. 2024; 22(1):207.

PMID: 38414006 PMC: 10897999. DOI: 10.1186/s12967-024-05001-4.